Search Results - "Brunvand, Mark M."

A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy by Giles, Francis J, Rodriguez, Roberto, Weisdorf, Daniel, Wingard, John R, Martin, Paul J, Fleming, Thomas R, Goldberg, Stuart L, Anaissie, Elias J, Bolwell, Brian J, Chao, Nelson J, Shea, Thomas C, Brunvand, Mark M, Vaughan, William, Petersen, Finn, Schubert, Mark, Lazarus, Hillard M, Maziarz, Richard T, Silverman, Margarida, Beveridge, Roy A, Redman, Rebecca, Pulliam, Janis G, Devitt-Risse, Patricia, Fuchs, Henry J, Hurd, David D

“…The invasion and colonization of oral cavity mucosal tissues by microflora may contribute to the pathophysiology of ulcerative oral mucositis (UOM). Iseganan…”
Get full text

A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial) by Giles, Francis J., Miller, Carole B., Hurd, David D., Wingard, John R., Fleming, Thomas R., Sonis, Stephen T., Bradford, Williamson Z., Pulliam, Janis G., Anaissie, Elias J., Beveridge, Roy A., Brunvand, Mark M., Martin, Paul J., PROMPT-CT Trial Investigators†

“…Microfloral invasion and colonization of oral cavity mucosal tissues contribute to the pathophysiology of ulcerative oral mucositis (UOM). Iseganan is an…”
Get full text